IPIX (Innovation Pharmaceuticals) Additional Paid-In Capital: $129.57 Mil(As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Innovation Pharmaceuticals Additional Paid-In Capital?

Innovation Pharmaceuticals IPIX Additional Paid-In Capital is $129.57 Mil as of Sep. 2023.


Innovation Pharmaceuticals's quarterly additional paid-in capital increased from Mar. 2023 ($129.56 Mil) to Jun. 2023 ($129.57 Mil) and increased from Jun. 2023 ($129.57 Mil) to Sep. 2023 ($129.57 Mil).

Innovation Pharmaceuticals's annual additional paid-in capital increased from Jun. 2021 ($124.84 Mil) to Jun. 2022 ($129.09 Mil) and increased from Jun. 2022 ($129.09 Mil) to Jun. 2023 ($129.57 Mil).

Innovation Pharmaceuticals Additional Paid-In Capital Related Terms

Innovation Pharmaceuticals Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Innovation Pharmaceuticals's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Innovation Pharmaceuticals Additional Paid-In Capital Chart

Innovation Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 90.54 102.82 124.84 129.09 129.57

Innovation Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 129.21 129.23 129.56 129.57 129.57

Innovation Pharmaceuticals Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $129.57 Mil mean?
Innovation Pharmaceuticals (IPIX) has a Additional Paid-In Capital of $129.57 Mil as of Sep. 2023. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Innovation Pharmaceuticals and its competitors.
Is Innovation Pharmaceuticals' Additional Paid-In Capital too high?
Innovation Pharmaceuticals' current Additional Paid-In Capital is $129.57 Mil.
How does Innovation Pharmaceuticals' Additional Paid-In Capital compare to AXIM and RNAZ?
Innovation Pharmaceuticals' Additional Paid-In Capital of $129.57 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Biotechnology company?
A good Additional Paid-In Capital depends on the Biotechnology industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Innovation Pharmaceuticals and its competitors. Innovation Pharmaceuticals's current Additional Paid-In Capital is $129.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Innovation Pharmaceuticals stock overvalued right now?
Innovation Pharmaceuticals (IPIX) has a current Additional Paid-In Capital of $129.57 Mil. The current Additional Paid-In Capital is $129.57 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Innovation Pharmaceuticals (IPIX), the current Additional Paid-In Capital is $129.57 Mil as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Innovation Pharmaceuticals Business Description

Address 301 Edgewater Place, Suite 100, Wakefield, MA, USA, 01880
Innovation Pharmaceuticals Inc is a clinical-stage pharmaceutical company in the United States. It is engaged in developing therapies with oncology, dermatology, and antimicrobial applications. Its clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Brilacidin, a potential therapeutic for the treatment of the novel coronavirus. The company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics, and inflammatory disease.